Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.7076
-0.0186 (-2.56%)
Feb 2, 2026, 3:44 PM EST - Market open
Ensysce Biosciences Employees
As of December 31, 2024, Ensysce Biosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$560,997
Profits / Employee
-$1,371,559
Market Cap
2.57M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 6 | 0 |
| Sep 30, 2021 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 4 | - | - | 4 | 0 |
| Dec 31, 2020 | 3 | - | - | 3 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| HCW Biologics | 36 |
| Lyra Therapeutics | 30 |
| Virax Biolabs Group | 19 |
| Cardio Diagnostics Holdings | 15 |
| Azitra | 12 |
| Onconetix | 5 |
| Bone Biologics | 2 |
ENSC News
- 5 days ago - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain - Accesswire
- 12 days ago - Ensysce Biosciences Expands Global Opioid Patent Portfolio - Accesswire
- 25 days ago - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Accesswire
- 26 days ago - Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 4 weeks ago - Ensysce Biosciences Issues Annual Shareholder Letter - Accesswire
- 7 weeks ago - Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - GlobeNewsWire
- 7 weeks ago - Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Accesswire
- 2 months ago - Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Accesswire